Page 1

November 15 , 2021 MindMed MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights ; Cash Balance of $ 145.9 USD ( $ 185.4 CAD ) to Execute on Diverse Clinical Pipeline NEW YORK , Nov. 15 , 2021 / CNW / -- MindMed ( Nasdaq : MNMD , NEO : MMED , DE : MMQ ) , a leading biotech company developing psychedelic - inspired therapies , has announced its quarterly financial results for the quarter ended September 30 , 2021 . MindMed Third Quarter 2021 Financial Highlights ( in USD ) • Cash Balance . Total assets as of September 30 , 2021 were $ 178.6 million , including $ 145.9 million in cash , as compared to $ 85.6 million , including $ 80.1 million in cash , as of December 31 , 2020 • Net Cash Used in Operating Activities . Net Cash Used in Operating Activities of $ 10.8 million and $ 31.9 million for the three and nine months ended September 30 , 2021 , as compared to $ 5.8 million and $ 16.5 million for the three and nine months ended September 30 , 2020 , respectively • Net Loss . Net and comprehensive loss of $ 24.3 million and $ 74.6 million for the three and nine months ended September 30 , 2021 , as compared to $ 8.6 million and $ 21.4 million for the three and nine months ended September 30 , 2020 Third Quarter 2021 Business Highlights • Announced the Appointment of Andreas Krebs and Carol Vallone as Board Directors and the Transition of Bruce Linton • Appointed three new members to its Scientific Advisory Board : Dr. Maria Oquendo , Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania and Psychiatrist - in - Chief at the Hospital of the University of Pennsylvania ; Dr. Bob Dworkin , Professor of Anesthesiology and Perioperative Medicine , Neurology , and